Clinical Trial Update: Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study of porfiromycin in head and neck cancer and other solid-tumor cancer patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Porfiromycin (porfiromycin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Neoplasms | Phase 1 | Status: TERMINATED